Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage

• Published in: Neurocritical care Vol. 36; no. 2; pp. 662 - 681
• Main Authors: Qureshi, Adnan I., Lobanova, Iryna, Huang, Wei, Ishfaq, Muhammad F., Broderick, Joseph P., Cassarly, Christy N., Martin, Renee H., Macdonald, R. Loch, Suarez, Jose I.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.04.2022; Springer Nature B.V
• Subjects: Aneurysms; Aspirin; Brain Ischemia - complications; Brain Ischemia - drug therapy; Cerebral Infarction - complications; Clinical trials; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care Medicine; Free radicals; Hemorrhage; Humans; Intensive; Internal Medicine; Ischemia; Medicine; Medicine & Public Health; Multicenter Studies as Topic; Muscle pain; Neurology; Neurosurgery; Nicardipine - therapeutic use; Nimodipine - therapeutic use; Nitric oxide; Pharmacists; Review Article; Smooth muscle; Stroke; Subarachnoid Hemorrhage - complications; Subarachnoid Hemorrhage - drug therapy; Subject heading schemes; Toxicity; Treatment Outcome; Vasospasm, Intracranial - complications; Vasospasm, Intracranial - etiology; New Zealand; Australia; North America; Europe; Disability; Phase III; Clinical trials; Death; Systematic review; Phase II; Aneurysmal subarachnoid hemorrhage

One of the challenges in bringing new therapeutic agents (since nimodipine) in for the treatment of cerebral ischemia associated with aneurysmal subarachnoid hemorrhage (aSAH) is the incongruence in therapeutic benefit observed between phase II and subsequent phase III clinical trials. Therefore, id...